EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An updated overview of the application of CAR‐T cell therapy in neurological diseases

Hesam Shahabifard, Mahdi Zarei, Keihan Kookli, Nazgol Esmalian Afyouni, Narges Soltani, Sairan Maghsoodi, Ali Adili, Javad Mahmoudi, Navid Shomali iD, Siamak Sandoghchian Shotorbani

Biotechnology Progress · 2023

DOI: 10.1002/btpr.3356 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biotechnology Progress, 2023. Verfasst von Hesam Shahabifard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Nervous System Diseases, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 119 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetically modified immune cells, especially CAR‐T cells, have captured the attention of scientists over the past 10 years. In the fight against cancer, these cells have a special place. Treatment for hematological cancers, autoimmune disorders, and cancers must include CAR‐T cell therapy. Determining the therapeutic targets, side effects, and use of CAR‐T cells in neurological disorders, including cancer and neurodegenerative diseases, is the goal of this study. Due to advancements in genetic engineering, CAR‐T cells have become crucial in treating some neurological disorders. CAR‐T cells have demonstrated a positive role in treating neurological cancers like Glioblastoma and Neuroblastoma due to their ability to cross the blood–brain barrier and use diverse targets. However, CAR‐T cell therapy for MS diseases is being researched and could be a potential treatment option. This study aimed to access the most recent studies and scientific articles in the field of CAR‐T cells in neurological diseases and/or disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nervous System DiseasesImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansAnimals

Stichwörter der Autor:innen

CAR-T cellsGBMSNBneurological disorders

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
  • International Campus, Iran University of Medical Sciences, Tehran, Iran.
  • Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
  • School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Laboratory Sciences, Faculty of Paramedical Sciences, Kurdistan University of Medical Sciences (MUK), Sanandaj, Iran.

ORCID-Profile: Navid Shomali

Zitieren

APA

Shahabifard, H., Zarei, M., Kookli, K., Esmalian Afyouni, N., Soltani, N., Maghsoodi, S., Adili, A., Mahmoudi, J., Shomali, N., & Sandoghchian Shotorbani, S. (2023). An updated overview of the application of CAR‐T cell therapy in neurological diseases. Biotechnology Progress. https://doi.org/10.1002/btpr.3356

Vancouver

Shahabifard H, Zarei M, Kookli K, Esmalian Afyouni N, Soltani N, Maghsoodi S, et al. An updated overview of the application of CAR‐T cell therapy in neurological diseases. Biotechnology Progress. 2023. doi:10.1002/btpr.3356

BibTeX
@article{Shahabifard2023,
  author = {Shahabifard, Hesam and Zarei, Mahdi and Kookli, Keihan and Esmalian Afyouni, Nazgol and Soltani, Narges and Maghsoodi, Sairan and Adili, Ali and Mahmoudi, Javad and Shomali, Navid and Sandoghchian Shotorbani, Siamak},
  title = {An updated overview of the application of CAR‐T cell therapy in neurological diseases},
  journal = {Biotechnology Progress},
  year = {2023},
  doi = {10.1002/btpr.3356}
}
Kostenlos starten →